With a long history of research in the field of gastrointestinal diseases, Ace Therapeutics is well positioned to provide clients with a wide range of research services during the development of antidiarrheal drugs.
Introduction to Antidiarrheal
Antidiarrheal drugs play an important role in the management of gastrointestinal disorders and are used to control diarrheal symptoms and reduce intestinal water-electrolyte loss.
- Acute Diarrhea
For acute diarrhea, loperamide is usually an option for rapid symptomatic relief, but should be used with caution in patients at risk of infectious diarrhea. Montmorillonite can also be used to absorb pathogenic toxins and protect the intestinal mucosa from viral or mildly infectious diarrhea.
- Chronic Diarrhea
For chronic diarrhea, such as irritable bowel syndrome-D, loperamide may be chosen to reduce the frequency of diarrhea episodes. Appropriate use of antidiarrheal agents may relieve non-infectious diarrhea, but should be avoided to avoid masking the risk of severe inflammation or bowel perforation.
Figure 1. A schematic view of IBS with diarrhea pathogenesis. (Wu X., et al., 2024)
Types of Antidiarrheal We Can Develop
- Intestinal Motility Inhibitors
Intestinal motility inhibitors selectively act on intestinal μ-opioid receptors to reduce propulsive intestinal motility. We can assist our clients in conducting ex vivo and in vivo efficacy studies of these drugs, such as evaluating the effects and mechanisms of the drugs in alleviating diarrhea symptoms by adsorbing toxins, microorganisms, or enhancing intestinal wall protection.
- Adsorbents and Protective Agents
Adsorbents and protective agents may reduce diarrheal symptoms by adsorbing toxins, microorganisms or enhancing intestinal wall protection. For these drugs, we can evaluate their efficacy in animal models for improving intestinal barrier function and reducing irritant damage to the intestinal mucosa.
- Microecological Regulators
Intestinal microecological modulators reestablish intestinal ecological balance, especially for infectious or antibiotic-associated diarrhea. We can help our clients to evaluate the ability of these drugs to reduce intestinal water and electrolyte secretion in an in vivo animal experimental model.
- Antisecretory Drugs
Intestinal antisecretory drugs alleviate diarrhea by inhibiting enteropeptidase and reducing intestinal water and electrolyte secretion. For these drugs, we can measure the inhibitory effect of the drugs on enteropeptidase in vitro and can assess their therapeutic effect on diarrhea in animal models.
What Can We Do for the Development of Antidiarrheal?
In Vitro Studies
- Intestinal Fluid Secretion Assay
Collect intestinal tissue from healthy animals and place it in an irrigation device containing simulated intestinal fluid to test the modulatory effects of antidiarrheal agents on intestinal fluid absorption and secretion.
- Intestinal Adsorption Capacity Assay
Test the adsorption capacity of antidiarrheal agents for water and toxins by simulating a diarrheal environment in vitro (such as adding toxins or hypertonic solutions).
- Intestinal Smooth Muscle Movement Experiments
Remove intestinal segments from experimental animals and placed them in a muscle strip tension recorder under ex vivo conditions to record the effects of antidiarrheal agents on intestinal smooth muscle tone and rhythmic contractions.
In Vivo Studies
Develop animal models of diarrhea to observe the actual efficacy of different types of antidiarrheal agents, to assess the relief of diarrheal symptoms, to explore the antidiarrheal mechanism, and to test the time of onset and duration of action.
- Chemically induced Diarrhea Models
- Infectious Diarrhea Models
- Stress Diarrhea Models
- Osmotic Diarrhea Models
Based on our specialized research team and technology platform, Ace Therapeutics can help pharmaceutical companies and research institutes develop novel therapies for the treatment of disorders caused by hyperacidity. If you are interested in our services, please do not hesitate to contact us.
Reference
- Wu, X.; et al. A new strategy for dietary nutrition to improve intestinal homeostasis in diarrheal irritable bowel syndrome: a perspective on intestinal flora and intestinal epithelial interaction. Nutrients. 2024, 16(18):3192.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
